Ann Rheum Dis

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS REGISTER
[Advanced]

Published Online First: 13 January 2006. doi:10.1136/ard.2005.045930
Annals of the Rheumatic Diseases 2006;65:1021-1027
Copyright © 2006 BMJ Publishing Group Ltd & European League Against Rheumatism

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
ard.2005.045930v1
65/8/1021    most recent
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this link to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Add article to my folders
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Krause, S
Right arrow Articles by Kloetzel, P-M
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Krause, S
Right arrow Articles by Kloetzel, P-M
Related Collections
Right arrow Connective tissue disease

EXTENDED REPORT

Immunoproteasome subunit LMP2 expression is deregulated in Sjögren’s syndrome but not in other autoimmune disorders

S Krause 1,2,4, U Kuckelkorn 1, T Dörner 3, G-R Burmester 2, E Feist 2,*, P-M Kloetzel 1,*

1 Institute of Biochemistry, Charité-University Medicine Berlin, Germany
2 Department of Medicine, Rheumatology and Clinical Immunology, Charité-University Medicine Berlin, Germany
3 Institute of Transfusion Medicine, Charité-University Medicine Berlin, Germany
4 Laboratory of Molecular Myology, Friedrich-Baur Institute, Department of Neurology, Ludwig-Maximilians University, Munich, Germany

Correspondence to:
Correspondence to:
Dr S Krause
Friedrich-Baur-Institute, Laboratory of Molecular Myology, Department of Neurology, Ludwig-Maximilians University, Marchioninistr 17, 81377 Munich, Germany; sabine.krause{at}med.uni-muenchen.de

Background: The proteasome system has a pivotal role in the control of the immune response, which suggests that it might be involved in the pathogenesis of autoimmune disorders.

Objective: To investigate the expression profile of selected proteasomal genes in human peripheral blood mononuclear cells in patients with a variety of autoimmune diseases compared with healthy subjects.

Methods: Real time quantitative RT-PCR was used to analyse the mRNA expression pattern of the proteasome activator subunits PA28{alpha} and PA28ß and of constitutive proteasome and interferon-{gamma}-inducible immunoproteasome subunits in peripheral blood mononuclear cells. Simultaneously, protein expression of selected proteasome subunits was quantified by immunoblotting.

Results: Under systemic inflammatory conditions the proteasome subunits LMP2 (ß1i), LMP7 (ß5i), MECL1 (ß2i), and PA28{alpha} were expressed abundantly at the protein level in the vast majority of systemic autoimmune disorders. However, simultaneous mRNA and protein quantification showed a characteristic proteasome expression signature in primary Sjögren’s syndrome. At the transcript level, the interferon-{gamma}-responsive subunits LMP2 (ß1i), MECL1 (ß2i), and the proteasome activator subunit PA28{alpha} were markedly up regulated. In contrast, LMP2 (ß1i) deficiency was evident at the protein level, indicating deregulation of proteasome expression in Sjögren’s syndrome.

Conclusions: These data provide evidence for a regulatory defect in the proteasome system in human autoimmune disorders, pointing to a unique role for LMP2 (ß1i) in the pathogenesis of primary Sjögren’s syndrome.


Abbreviations: HPRT, hypoxanthine phosphoribosyl transferase; IFN{gamma}, interferon {gamma}; LMP, low molecular weight protein; MECL1, multicatalytic endopeptidase complex-like 1; MHC, major histocompatibility complex; NOD, non-obese diabetic; PM, polymyositis; RA, rheumatoid arthritis; PA, proteasome activator; pSS, primary Sjögren’s syndrome; RT-PCR, reverse transcriptase-polymerase chain reaction; SLE, systemic lupus erythematosus; SSc, systemic sclerosis

Keywords: proteasome; autoimmune disorders; Sjögren’s syndrome; real time quantitative RT-PCR; interferon {gamma}




This article has been cited by other articles:


Home page
Ann Rheum DisHome page
S. D Tran, S. Kodama, B. M Lodde, I. Szalayova, S. Key, S. Khalili, D. L Faustman, and E. Mezey
Reversal of Sjogren's-like syndrome in non-obese diabetic mice
Ann Rheum Dis, June 1, 2007; 66(6): 812 - 814.
[Abstract] [Full Text] [PDF]


Home page
Adv. Physiol. Educ.Home page
E. Dale, M. Davis, and D. L. Faustman
A role for transcription factor NF-{kappa}B in autoimmunity: possible interactions of genes, sex, and the immune response
Advan Physiol Educ, December 1, 2006; 30(4): 152 - 158.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS REGISTER
Terms and conditions relating to subscriptions purchased online  ¦  Website terms and conditions  ¦  Privacy policy
Copyright © 2006 BMJ Publishing Group Ltd & European League Against Rheumatism